Cardioprotection with GLP-1: What the SELECT and FLOW Trials Show

A few years ago, GLP-1-based medications were known mainly for helping control blood sugar and aiding weight loss. Today the conversation is different. Large-scale clinical trials like SELECT and FLOW revealed something that changed how cardiologists and endocrinologists view these drugs: the cardiovascular benefit goes far beyond glucose reduction.

If you take GLP-1 or are considering starting treatment, understanding what the science found is key to making well-informed decisions.

What the SELECT Trial Showed

SELECT was a massive study with more than 17,600 participants, all with established cardiovascular disease but no diabetes diagnosis. Half received injectable semaglutide at a dose of 2.4 mg per week, and the other half received a placebo. The follow-up lasted approximately three years.

The results were striking. The group using semaglutide showed a 20% reduction in major cardiovascular events, such as non-fatal heart attacks and strokes. That number is nothing to dismiss. It represents a real difference in the lives of thousands of people.

There was also a reduction in mortality from cardiovascular causes. For those who already have heart disease, GLP-1 offered a layer of protection that goes beyond weight control.

And FLOW, What Did It Bring?

FLOW had a different focus. It brought together more than 5,000 patients with type 2 diabetes and chronic kidney disease, evaluating weekly semaglutide versus placebo. The primary goal was to observe kidney disease progression and combined cardiovascular outcomes.

The findings confirmed what many specialists suspected. Semaglutide significantly reduced kidney disease progression and cardiovascular events compared to placebo. The risk reduction for events like heart attacks and cardiovascular death was around 18%.

This is particularly relevant because kidney and cardiovascular disease tend to walk together, especially in patients with diabetes. Protecting both kidneys and heart at the same time represents a significant advantage.

Why GLP-1 Protects the Heart

The mechanisms behind this cardioprotection are still being studied, but it is already known that they go beyond weight loss. Chronic inflammation plays a central role in the development of cardiovascular disease, and GLP-1 agonists appear to consistently reduce inflammatory markers.

There is also an effect on endothelial function, which is the ability of blood vessels to dilate and regulate flow. Healthier vessels mean less plaque buildup and lower risk of obstruction.

In addition, these medications help control blood pressure and improve the lipid profile, even without major weight changes. All of this creates a less hostile environment for the cardiovascular system.

What This Means in Practice

These results are not just study numbers. They represent a shift in the role of GLP-1 medications in treating patients with cardiovascular risk. Before, the decision to use these drugs revolved around glycemic control and weight loss. Now, even patients without diabetes can benefit from this class of medications to protect the heart.

For those already using GLP-1, this evidence reinforces that long-term treatment brings advantages that go beyond aesthetics or sugar control. Regular medical follow-up remains essential to adjust doses and monitor side effects.

For those thinking about starting treatment, it is worth talking to your doctor about how a support platform can help maintain consistency in medication use. You can find more information by clicking here and better understand how a support tool accompanies people using GLP-1 therapy.

The Role of Ongoing Support

A point that is often lost in this conversation is the importance of adherence. Clinical trials have structure and intensive follow-up that ensure participants take the medication consistently. In real life, maintaining regularity is the great challenge.

Tools that help monitor symptoms, side effects, and practical outcomes make a real difference. Ozempro allows you to record how you feel over the weeks, making it easier to identify patterns and adjust habits. Many people who use GLP-1 without adequate support stop prematurely because they do not notice the initial benefits or because they cannot manage side effects that could have been controlled.

Having a personal history of how your body responds to treatment empowers you to have more productive conversations with your doctor. And that directly impacts long-term results.

Practical Tips to Maximize the Benefits

Maintaining a routine helps. Applying the medication on the same day and time each week reduces the chance of forgetting doses. Writing down how you feel in the days following the injection can reveal whether there are predictable side effects you can anticipate.

Food matters too. You do not need to follow restrictive diets, but choosing whole foods and reducing ultra-processed foods helps minimize gastrointestinal effects, which are the most common at the start of treatment.

Finally, do not underestimate the impact of sleep and movement. People who maintain a regular sleep routine and moderate physical activity tend to tolerate treatment better and show more consistent results. Ozempro offers resources to track these changes and keep a record of your progress without complications.

What Comes Next

Research on GLP-1 and cardiovascular health continues to advance. New studies are underway to evaluate drug combinations, effects on younger populations, and potential benefits in conditions such as heart failure.

What is known so far is enough to consider these medications as a valuable tool in preventing cardiovascular events, especially in patients with multiple risk factors. The decision to use GLP-1 should be made together with a healthcare professional, considering personal history, coexisting conditions, and treatment goals.

The SELECT and FLOW trials confirmed that semaglutide reduces cardiovascular events consistently, regardless of the presence of diabetes. This cardioprotection adds to the already known benefits in glycemic control and weight loss, expanding the role of these medications in clinical practice.

References

• EMA — Ozempic (semaglutida), EPAR
• Wilding et al., STEP 1 — NEJM (2021)
• Lincoff et al., SELECT — NEJM (2023)